Media.Player

Production of Biologically Active Human Recombinant Insulin‐like Growth Factor‐I and Human Insulin‐like Binding Protein‐3 in Transgenic Rice for the Management of Diabetes, Obesity, Cancer and their Related Diseases

總結

Diabetes mellitus is a common chronic disease affecting more than 10% of our population and will lead to devastating complications. Abnormal growth hormone/ insulin-like growth factor-I regulation contributes to the deterioration in glycaemic control in patients with insulin deficiency. Treatment with recombinant human insulin-like growth factor I (rhIGF-I) has been shown to reduce plasma glucose and insulin doses in both type 1 and type 2 diabetic patients. Recently, it has been demonstrated that co-administration of rhIGF-I with recombinant IGF Binding Protein 3 (rhIGFBP-3) can reduce the side effects without affecting the therapeutic efficacy. In addition to its high-binding activity to IGFs, IGFBP-3 has been found to negatively regulate cell proliferation and induce apoptosis in an IGF-independent manner. This may be an attractive feature in the potential development of IGFBP-3 as an anticancer agent. An efficient bioreactor platform for mass production of rhIGF-I and rhIGFBP-3 in transgenic rice has been identified. Results showed that transgenic plants can be developed as bioreactor for the synthesis of hIGF-I and hIGFBP-3 and the plant-produced recombinant proteins were biologically active.

237 non-conf abstract_hkstp Page 1 of 1

申請號碼

06/SCI/237 Inventors: Professor Samuel SUN, Department of Biology Professor TONG Chun Yip Peter, Department of Medicine and Therapeutics Mr. CHEUNG Chun Kai Stanley, Department of Medicine and Therapeutics Patent Status: US Patent and PCT Pending

國家/地區

香港